1-3 of 3
Max Yano
Close
Sort by
Journal Articles

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy

Max Yano, Chia Sharpe, J. Rachel Lance, Janani Ravikrishnan, Kevan Zapolnik, Xiaokui Mo, Jennifer A. Woyach, Deepa Sampath, Adam S. Kittai, Sumithira Vasu, Seema Bhat, Kerry A. Rogers, Dean A. Lee, Natarajan Muthusamy, John C. Byrd
Journal: Blood Advances
Blood Adv (2022) 6 (20): 5641–5654.
https://doi.org/10.1182/bloodadvances.2021005883
Published: 2022
Includes: Supplemental data
Journal Articles

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL

Max Yano, Jessica Nunes, Xiaokui Mo, Kerry A. Rogers, Jennifer A. Woyach, John C. Byrd, Natarajan Muthusamy
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5440–5448.
https://doi.org/10.1182/bloodadvances.2021005571
Published: 2022
Journal Articles

Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling

J. T. Greene, Rajeswaran Mani, Rahul Ramaswamy, Frank Frissora, Max Yano, Kevan Zapolnik, Bonnie Harrington, Ronni Wasmuth, Minh Tran, Xiaokui Mo, Mary McKenna, Vivek M. Rangnekar, John C. Byrd, Subbarao Bondada, Natarajan Muthusamy
Journal: Blood Advances
Blood Adv (2019) 3 (8): 1255–1266.
https://doi.org/10.1182/bloodadvances.2018025973
Published: 2019
Includes: Supplemental data